Back to search

France· FR:69082804

METVIXIA 168 mg/g, crème

A methyl aminolevulinate product containing chlorhydrate de méthyl aminolévulinate, registered in France by GALDERMA INTERNATIONAL, on the national reimbursement list. The same ATC class is registered in 13 of our 19 countries.

Reimbursed in France (Assurance maladie)ATC L01XD03

Checked against Base de données publique des médicaments — BDPM (France) on

Informational only — not a medical device.

SOURCE REGISTER · FRBase de données publique des médicament…normalisedMETVIXIA 168 mg/g, crèmeATCL01XD03REGISTER NO.FR:69082804PACKS LISTED1CHECKEDSeptember 12, 2026

Where it is registered

Methyl aminolevulinate is registered in 13 of 19 countries.

Countries holding a registration under ATC L01XD03 (methyl aminolevulinate), each read from that country’s own register.

  • This record: France, from Base de données publique des médicaments — BDPM (France)
  • 7 of them publish a price we can compare per daily dose

Methyl aminolevulinate · ATC L01XD03

13 / 19 countries

  • Belgiumprice
  • Canada
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Base de données publique des médicaments — BDPM (France)
Active substance
CHLORHYDRATE DE MÉTHYL AMINOLÉVULINATE
Manufacturer
GALDERMA INTERNATIONAL
Country
France (FR)
ATC code
L01XD03
ATC class
Methyl aminolevulinate
Reimbursed
Yes
Source register
Base de données publique des médicaments — BDPM (France)
Last checked
September 12, 2026

Packs & prices · 1

1 priced
  • cip13
    3400937719858
    1 tube(s) aluminium verni de 2 g
    EUR 179.65

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Methyl aminolevulinate in 11 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All methyl aminolevulinate products

Authorised across Europe · EMA

The same active substance is authorised in 18 EEA countries. Names it is sold under:

  • Austria · Luxerm, Metvix
  • Belgium · Metvix
  • Germany · Luxerm, Metvix
  • Denmark · Metvix
  • Spain · Metvix
  • Finland · Metvix
  • United Kingdom (Northern Ireland) · Metvix
  • Greece · Metvix
  • Ireland · Metvix
  • Iceland · Metvix
  • Italy · Metvix
  • Luxembourg · Metvix
  • Malta · Metvix
  • Netherlands · Metvix
  • Norway · Metvix
  • Portugal · Metvix
  • Sweden · Luxera, Metvix
  • Slovakia · Metvix

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/08b994e5-d2cb-4b92-b23a-145b4652c10c
GET /v1/drugs/08b994e5-d2cb-4b92-b23a-145b4652c10c?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "cis": "69082804",
  "date_amm": "2006-09-19",
  "type_amm": "Procédure nationale",
  "numero_ue": null,
  "substance": "CHLORHYDRATE DE MÉTHYL AMINOLÉVULINATE",
  "atc_source": "fr_atc_restore_2026-09-06",
  "statut_amm": "Autorisation active",
  "statut_bdm": null,
  "forme_pharmaceutique": "crème",
  "voies_administration": "cutanée",
  "etat_commercialisation": "Commercialisée",
  "surveillance_renforcee": "Non"
}

See everything about methyl aminolevulinate.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.